Stock DARE DARÉ BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Delayed Nasdaq
Other stock markets
 02:31:44 2024-04-29 pm EDT 		5-day change 1st Jan Change
0.2896 USD -5.33% Intraday chart for Daré Bioscience, Inc. -1.93% -6.28%
Apr. 23 Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 CI
Mar. 28 Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
AQ
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
CI
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
AQ
Transcript : Daré Bioscience, Inc., 2023 Earnings Call, Mar 28, 2024
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
AQ
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
AQ
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
AQ
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
AQ
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
CI
Daré Bioscience, Inc. Announces Executive Changes
CI
Daré Bioscience, Inc. Announces the Resignation of Lisa Walters-Hoffert as Chief Financial Officer
CI
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned
MT
Daré Bioscience Announces Executive Team and Board of Directors Changes
AQ
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
AQ
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
AQ
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
AQ
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
AQ
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study
CI
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DARE Stock
  4. News Daré Bioscience, Inc.